PRQR Key Statistics, Chart & Performance
The current stock price of PRQR is 2.17 USD. In the past month the price increased by 0.93%. In the past year, price decreased by -22.22%.
PRQR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About PRQR
Company Profile
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Company Info
PROQR THERAPEUTICS NV
Zernikedreef 9
Leiden ZUID-HOLLAND 2333 CK NL
CEO: Daniel de Boer
Employees: 166
Phone: 31881667000
PROQR THERAPEUTICS NV / PRQR FAQ
What does PROQR THERAPEUTICS NV do?
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
What is the current price of PRQR stock?
The current stock price of PRQR is 2.17 USD. The price decreased by -1.81% in the last trading session.
Does PROQR THERAPEUTICS NV pay dividends?
PRQR does not pay a dividend.
What is the ChartMill rating of PROQR THERAPEUTICS NV stock?
PRQR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for PRQR stock?
The Revenue of PROQR THERAPEUTICS NV (PRQR) is expected to decline by -24.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is PROQR THERAPEUTICS NV worth?
PROQR THERAPEUTICS NV (PRQR) has a market capitalization of 228.61M USD. This makes PRQR a Micro Cap stock.
What is the ownership structure of PROQR THERAPEUTICS NV (PRQR)?
You can find the ownership structure of PROQR THERAPEUTICS NV (PRQR) on the Ownership tab.
PRQR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PRQR. When comparing the yearly performance of all stocks, PRQR is a bad performer in the overall market: 77.29% of all stocks are doing better.
PRQR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRQR. PRQR has a bad profitability rating. Also its financial health evaluation is rather negative.
PRQR Financial Highlights
Over the last trailing twelve months PRQR reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS decreased by -42.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.23% | ||
| ROE | -74.59% | ||
| Debt/Equity | 0.18 |
PRQR Forecast & Estimates
15 analysts have analysed PRQR and the average price target is 9.76 USD. This implies a price increase of 349.9% is expected in the next year compared to the current price of 2.17.
For the next year, analysts expect an EPS growth of -36.74% and a revenue growth -24.03% for PRQR